Fetal and Neonatal Alloimmune Thrombocytopenia
Symptoms, Doctors, Treatments, Advances & More

Fetal and Neonatal Alloimmune Thrombocytopenia Overview

Save information for later
Sign Up

Learn About Fetal and Neonatal Alloimmune Thrombocytopenia

What is the definition of Fetal and Neonatal Alloimmune Thrombocytopenia?
Fetal and neonatal alloimmune thrombocytopenia (NAIT) is a blood disorder that affects pregnant women and their babies. NAIT was first reported in the literature in 1953 and is estimated to occur in as many as 1 in 1200 live births. NAIT results in the destruction of platelets in the fetus or infant due to a mismatch between the mother's platelets and those of the baby. Certain molecules (antigens) on the surface of the baby's platelets are recognized as foreign by the mother's immune system. The mother's immune system then creates antibodies that attack and destroy the baby's platelets. Though NAIT can occur whenever the mother's blood mixes with that of the baby, it is usually triggered when the mother is exposed to the baby's blood during delivery. Many cases of NAIT are mild. Signs and symptoms may include a low platelet count (thrombocytopenia) and signs of bleeding into the skin such as petechiae and purpura. In the most severe cases, NAIT can cause bleeding episodes that may result in death or long-term disability. Bleeding episodes can occur either during pregnancy or after birth.
What are the alternative names for Fetal and Neonatal Alloimmune Thrombocytopenia?
  • Fetal and neonatal alloimmune thrombocytopenia
  • NAIT
Who are the top Fetal and Neonatal Alloimmune Thrombocytopenia Local Doctors?
Elite in Fetal and Neonatal Alloimmune Thrombocytopenia
Jens Kragh-Kjeldsen
Elite in Fetal and Neonatal Alloimmune Thrombocytopenia
Jens Kragh-Kjeldsen
Lund, M, SE 

Jens Kragh-Kjeldsen practices practicing medicine in Lund, Sweden. Mr. Kragh-Kjeldsen is rated as an Elite expert by MediFind in the treatment of Fetal and Neonatal Alloimmune Thrombocytopenia. He is also highly rated in 2 other conditions, according to our data. His clinical expertise encompasses Fetal and Neonatal Alloimmune Thrombocytopenia, Thrombocytopenia, ABO Incompatibility, and Hemolytic Disease of the Newborn.

Elite in Fetal and Neonatal Alloimmune Thrombocytopenia
Heidi Tiller
Elite in Fetal and Neonatal Alloimmune Thrombocytopenia
Heidi Tiller
Tromso, NO 

Heidi Tiller practices practicing medicine in Tromso, Norway. Ms. Tiller is rated as an Elite expert by MediFind in the treatment of Fetal and Neonatal Alloimmune Thrombocytopenia. She is also highly rated in 2 other conditions, according to our data. Her clinical expertise encompasses Fetal and Neonatal Alloimmune Thrombocytopenia, Thrombocytopenia, and ABO Incompatibility.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Fetal and Neonatal Alloimmune Thrombocytopenia
Cecile Kaplan
Elite in Fetal and Neonatal Alloimmune Thrombocytopenia
Cecile Kaplan
Paris, FR 

Cecile Kaplan practices practicing medicine in Paris, France. Ms. Kaplan is rated as an Elite expert by MediFind in the treatment of Fetal and Neonatal Alloimmune Thrombocytopenia. She is also highly rated in 2 other conditions, according to our data. Her clinical expertise encompasses Fetal and Neonatal Alloimmune Thrombocytopenia and Thrombocytopenia.

View All Doctors
What are the latest Fetal and Neonatal Alloimmune Thrombocytopenia Clinical Trials?
Multicenter, Open-Label, Randomized Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
Multicenter, Open-Label, Randomized Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
Enrollment Status: Recruiting
Publish Date: April 13, 2026
Intervention Type: Drug
Study Phase: Phase 3

Summary: The purpose of this study is to assess the efficacy and safety of nipocalimab in reducing the risk of severe fetal and neonatal alloimmune thrombocytopenia (FNAIT).

Match to trials
Find the right clinical trials for you in under a minute
Get started
Double-blind, Randomized, Placebo-controlled Study Evaluating the Safety and Efficacy of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) in At-risk Pregnancies
Double-blind, Randomized, Placebo-controlled Study Evaluating the Safety and Efficacy of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) in At-risk Pregnancies
Enrollment Status: Recruiting
Publish Date: April 13, 2026
Intervention Type: Drug
Study Phase: Phase 3

Summary: The purpose of this study is to evaluate the effectiveness of nipocalimab compared with placebo in reducing the risk of severe fetal and neonatal alloimmune thrombocytopenia (FNAIT).

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center